FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|July 8, 2021
COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of July 8, 2021
Author(s)Sydney Jennings
Global confirmed deaths due to COVID-19 have surpassed 4 million. We summarize more of today's data from the Johns Hopkins COVID-19 interactive map and the CDC.
Advertisement
How widespread is the Delta variant (B.1.617.2) in the US?
According the US
1. Missouri: 73.3%
2. Nevada: 39.7%
3. Colorado: 36.3%
4. California: 29.6%
5. New Jersey: 27.6%
2. Nevada: 39.7%
3. Colorado: 36.3%
4. California: 29.6%
5. New Jersey: 27.6%
How many people in the US have been vaccinated against COVID-19?
According to the CDC , as of today, July 8, 2021, at 3:21 PM, EDT:
• 55.2% of total US population has received at least 1 dose
• 47.7% of total US population is fully vaccinated
• 47.7% of total US population is fully vaccinated
The 5 states with the highest percentage of population fully vaccinated are:
1. Vermont: 66.2%
2. Massachusetts: 62.3%
3. Maine: 62.2%
4. Connecticut: 61.4%
5. Rhode Island: 59.6%
2. Massachusetts: 62.3%
3. Maine: 62.2%
4. Connecticut: 61.4%
5. Rhode Island: 59.6%
How many cases of COVID-19 have been confirmed in the US?
According to the
• 33 780 614 confirmed cases
• 606 376 deaths
• 606 376 deaths
The 5 states with the highest total confirmed cases are:
1. California: 3 828 338
2. Texas: 3 011 214
3. Florida: 2 381 148
4. New York: 2 118 216
5. Illinois: 1 394 852
2. Texas: 3 011 214
3. Florida: 2 381 148
4. New York: 2 118 216
5. Illinois: 1 394 852
Deaths: California has the most deaths due to COVID-19 with 63 806 reported fatalities, followed by New York with 53 719, and Texas with 52 541.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 185 325 890 confirmed cases, 4 005 635 deaths, and 3 347 835 942 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
2
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
5 FDA Decisions for Primary Care to Know from September 2026
5